Literature DB >> 12618274

Insulin sensitivity and plasma homocysteine concentrations in non-diabetic obese and normal weight subjects.

Vivian A Fonseca1, Louis M Fink, Philip A Kern.   

Abstract

OBJECTIVE: To determine whether plasma homocysteine (tHcy) levels were related to insulin resistance and obesity in subjects without diabetes or vascular disease. RESEARCH DESIGN AND METHODS: We studied correlates of plasma tHcy in 26 subjects covering a wide spectrum of obesity and insulin sensitivity (S(I)). The measurement of in vivo insulin sensitivity was performed using the minimal model analysis of the frequently sampled intravenous glucose tolerance test (FSIVGTT).
RESULTS: There was no relationship between tHcy and body mass index. There was a significant relationship between plasma tHcy and S(I) (r=0.53, P=0.006), demonstrating that the more insulin sensitive subjects had higher levels of tHcy. On log transformation of the plasma insulin values, log insulin correlated negatively with plasma tHcy (r=-0.47; P=0.02). None of the subjects were deficient in vitamin B(12) and folate. Plasma vitamin B(12) was significantly related to plasma tHcy (r=-0.44, P=0.017), although we found no significant relationship between plasma folate and tHcy (r=-0.21, P=0.27). S(I) correlated significantly with vitamin B(12) (r=0.4, P=0.045) whereas, we found no significant relationship between S(I) and plasma folate (r=0.27, P=0.2). On multiple linear regression using tHcy as the dependent variable, S(I) and vitamin B(12) remained significant predictors of plasma tHcy, whereas, age and plasma folate were not predictors of tHcy.
CONCLUSIONS: We conclude that in vitamin replete lean and obese individuals, insulin sensitivity correlates significantly with plasma tHcy. This relationship may need to be considered when evaluating the role of plasma homocysteine as a risk factor in patients with obesity and type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12618274     DOI: 10.1016/s0021-9150(02)00386-6

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  25 in total

1.  Homocysteine suppresses lipolysis in adipocytes by activating the AMPK pathway.

Authors:  Zhigang Wang; Maria Pini; Tong Yao; Zhanxiang Zhou; Changhao Sun; Giamila Fantuzzi; Zhenyuan Song
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-07-12       Impact factor: 4.310

2.  Plasma total homocysteine level and its association with carotid intima-media thickness in obesity.

Authors:  O Uysal; E Arikan; B Cakir
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

3.  Mild hyperhomocysteinemia and the common C677T polymorphism of methylene tetrahydrofolate reductase gene are not associated with the metabolic syndrome in Type 2 diabetes.

Authors:  G T Russo; A Di Benedetto; E Alessi; R Ientile; A Antico; G Nicocia; R La Scala; E Di Cesare; G Raimondo; D Cucinotta
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

4.  Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine.

Authors:  Satish C Kalhan; John Edmison; Susan Marczewski; Srinivasan Dasarathy; Lourdes L Gruca; Carole Bennett; Clarita Duenas; Rocio Lopez
Journal:  Clin Sci (Lond)       Date:  2011-08       Impact factor: 6.124

5.  Homocysteine inhibits adipogenesis in 3T3-L1 preadipocytes.

Authors:  Zhigang Wang; Xiaobing Dou; Tong Yao; Zhenyuan Song
Journal:  Exp Biol Med (Maywood)       Date:  2011-11-23

6.  Are genetic variants of the methyl group metabolism enzymes risk factors predisposing to obesity?

Authors:  I Terruzzi; P Senesi; I Fermo; G Lattuada; L Luzi
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

7.  Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

Authors:  Paras K Mishra; Neetu Tyagi; Utpal Sen; Irving G Joshua; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2010-09-09       Impact factor: 9.951

8.  Associations between medication use and homocysteine levels in an older population, and potential mediation by vitamin B12 and folate: data from the B-PROOF Study.

Authors:  Annelies C Ham; Anke W Enneman; Suzanne C van Dijk; Sadaf Oliai Araghi; Karin M A Swart; Evelien Sohl; Janneke P van Wijngaarden; Nikita L van der Zwaluw; Elske M Brouwer-Brolsma; Rosalie A M Dhonukshe-Rutten; Natasja M van Schoor; Tischa J M van der Cammen; M Carola Zillikens; Robert de Jonge; Paul Lips; Lisette C P G M de Groot; Joyce B J van Meurs; André G Uitterlinden; Renger F Witkamp; Bruno H C Stricker; Nathalie van der Velde
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

9.  Effect of homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial.

Authors:  Yiqing Song; Nancy R Cook; Christine M Albert; Martin Van Denburgh; JoAnn E Manson
Journal:  Diabetes       Date:  2009-06-02       Impact factor: 9.461

10.  Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome.

Authors:  Stefano Palomba; Angela Falbo; Francesco Giallauria; Tiziana Russo; Achille Tolino; Fulvio Zullo; Annamaria Colao; Francesco Orio
Journal:  Diabetes Care       Date:  2009-11-23       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.